CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($) shares in Thousands, $ in Millions		Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Balance at Dec. 31, 2017		$ (714.7)	$ (41.1)	$ 189.7	$ 2,291.2	$ 2,320.3	$ (41.1)	$ (926.2)	$ (4,600.0)	$ 10.3
Balance (in shares) at Dec. 31, 2017				758,700					318,400
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(21.8)				(19.5)				(2.3)
Other comprehensive income (loss)		(104.4)						(104.2)		(0.2)
Dividends accrued - preferred stock		(24.3)				(24.3)
Exercise/ vesting/ expense of share-based compensation		12.8		$ 0.7	12.4	(1.1)			$ 0.8
Exercise/ vesting/ expense of share-based compensation (in shares)				3,100					(100)
Repurchase of common stock		(3.2)		$ (0.1)					$ (3.1)
Repurchase of common stock (in shares)									(1,100)
Purchases and sales of noncontrolling interests, net of dividends paid		(0.1)								(0.1)
Balance at Dec. 31, 2018		$ (896.8)		$ 190.3	2,303.6	2,234.3		(1,030.4)	$ (4,602.3)	7.7
Balance (in shares) at Dec. 31, 2018				761,800					319,400
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201613Member
Net loss		$ (1.3)				(0.3)				(1.0)
Other comprehensive income (loss)		(9.4)						(9.6)		0.2
Dividends accrued - preferred stock		(25.5)				(25.5)
Dividends accrued - common stock		(8.7)				(8.7)
Exercise/ vesting/ expense of share-based compensation		28.5		$ 2.6	25.9
Exercise/ vesting/ expense of share-based compensation (in shares)				9,900
Repurchase of common stock		(9.6)		$ (0.3)	(8.3)				$ (1.0)
Repurchase of common stock (in shares)				(1,700)					(500)
Remeasurement of Series C convertible preferred stock		(60.9)				(60.9)
Purchases and sales of noncontrolling interests, net of dividends paid		(0.1)								(0.1)
Balance at Dec. 31, 2019		(983.8)	$ (2.0)	$ 192.6	2,321.2	2,138.9	$ (2.0)	(1,040.0)	$ (4,603.3)	6.8
Balance (in shares) at Dec. 31, 2019				770,000					319,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Gain on common control transaction		1.4				1.4
Capitalization of payable	[1]	91.5			91.5
Net loss		(365.5)				(362.8)				(2.7)
Other comprehensive income (loss)		(93.6)						(93.8)		0.2
Conversion of Series C convertible preferred stock (in shares)	[2]								(87,000)
Conversion of Series C convertible preferred stock	[2]	486.8				(710.8)			$ 1,197.6
Exercise/ vesting/ expense of share-based compensation		(2.0)		$ (0.2)	(1.8)
Exercise/ vesting/ expense of share-based compensation (in shares)				0
Exchange of common stock (in shares)	[3]			(770,000)					(232,900)
Exchange of common stock	[3]	0.0		$ (192.4)	(1,788.1)	(1,425.2)			$ 3,405.7
Balance at Dec. 31, 2020	[4]	$ (867.2)		$ 0.0	$ 622.8	$ (360.5)		$ (1,133.8)	$ 0.0	$ 4.3
Balance (in shares) at Dec. 31, 2020	[4]			0					0

[1] In January 2020 Natura &Co Holding paid the accrued dividends on the shares of series C preferred stock in an amount equal to U.S. $91.5 to Cerberus, resulting in a payable due to an affiliate of Natura &Co Holding for the same amount. See Note 17, Series C Convertible Preferred Stock, for discussion of preferred shares issued to Cleveland Apple Investor L.P. (“Cerberus Investor”). During 2020, the payable due to Natura &Co was capitalized and recorded as a capital contribution through Additional Paid in Capital.

[2] On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below). See Note 17, Series C Convertible Preferred Stock.

[3] In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 21, Mergers     with Natura Cosméticos S.A.,.

[4] The number of shares of Common Stock (par value $0.01 per share) outstanding at December 31, 2020 was 101.34.